Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

HydraMed IV LLC dba HydraMed

Has HydraMed received an FDA warning letter? Yes. FDA issued a warning letter dated June 8, 2026 concerning products containing semaglutide and tirzepatide.

Letter facts

Letter date
June 8, 2026 (2026-06-08)
Issuing office
Center for Drug Evaluation and Research (CDER)
Recipient type
Telehealth
Products named
compounded drug productssemaglutide productstirzepatide products
Violation categories
MisbrandingFalse or misleading claims

Understanding these violation categories

Misbranding

FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.

False or misleading claims

FDA says the company made claims regarding product equivalence, safety, or FDA approval that were inaccurate or not supported by evidence. A warning letter notifies the recipient to bring promotions into compliance.

Factual Violation Summary

FDA says the website falsely suggested HydraMed compounded semaglutide and tirzepatide, and claimed products were sourced from an 'FDA-approved pharmacy'; FDA deemed these representations false or misleading, causing misbranding under FD&C Act sections 502(a) and 502(bb).

Active Drug Ingredients

Statutory Citations & Specific Allegations

  • misbranding under FD&C Act §§ 502(a) and 502(bb)
  • false or misleading labeling and advertising
  • introduction into interstate commerce of misbranded drug products under § 301(a)

More letters about Semaglutide

Recent FDA warning letters concerning Semaglutide:

Similar violations (Misbranding)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.